Vical Incorporated using SYMBOL code NASDAQ:VICL had its stock rating noted as ‘Coverage Initiated’ with the recommendation being set at ‘BUY’ today by analysts at ROTH Capital. Vical Incorporated are listed in the Health Care sector within NASDAQ. ROTH Capital have set a target price of 4.65 USD on its stock. This now indicates the analyst believes there is a potential upside of 428.4% from today’s opening price of 0.88 USD. Vical Incorporated NASDAQ:VICL has a 50 day moving average of .96 USD and the 200 Day Moving Average price is recorded at 1.08 USD. The 52 week high for the stock is 1.39 USD while the year low share price is currently 0.85 USD.
Vical Incorporated NASDAQ:VICL researches and develops biopharmaceutical products based on its deoxyribonucleic acid (DNA) delivery technologies for the prevention and treatment of serious or life-threatening diseases. The Company has three active independent and partnered development programs in the areas of infectious disease consisted of Phase III clinical trial of ASP0113 for prevention of cytomegalovirus (CMV), reactivation in stem cell transplant recipients and Phase II clinical trial of ASP0113 for prevention of CMV infection in kidney transplant recipients; Phase I/II clinical trial using its Vaxfectin formulated therapeutic vaccine for herpes simplex virus type 2, or HSV-2, a cause of recurrent genital herpes, and a completed preclinical program, with an investigational new drug application (IND), using its CyMVectin prophylactic vaccine formulated with its Vaxfectin adjuvant to prevent CMV infection before and during pregnancy.